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INTRODUCTION 
 Statins are the most commonly prescribed drug in the world, used in many 
chronic conditions like cardiovascular diseases, cerebrovascular diseases, 
peripheral vascular diseases, and diabetes mellitus for long duration. (1), (2) 
 
           It is one of the best selling drugs in the world. Statins are perceived to have 
favorable safety profile and benefits in cardiovascular disease. Although many 
people consume this drug, there is need to highlight potential adverse effects and 
create awareness of risk as well as benefits, particularly drugs like statins which 
are used to have a wide scale where uncommon adverse effects can have 
significant public health impact. 
 
 Statins acts by inhibiting the HMG CO-A reductase enzyme thereby 
inhibits the conversion of HMG CO-A to mevalonate, which is the precursor for 
cholesterol and thereby reduces cholesterol production. (3) 
 
 Nearly half of the body cholesterol need is provided by diet and the 
remaining half is synthesized in the body itself. (4) 
 
 Even though all the tissues can synthesize cholesterol, mainly liver, 
intestine, ovaries, testes, adrenal cortex, nervous tissue and skin contributes large 
amount in the body cholesterol pool (5) 
 Endogenous cholesterol is synthesized from acetyl Co-A. In the process of 
cholesterol synthesis from acetyl CoA, conversion of 3-Hydroxy-3-methyl 
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glutaryl coenzyme A (HMG CO-A) to mevalonate is catalyzed by a rate limiting 
enzyme HMG CO-A reductase.(6) 
 
 Cholesterol is an important constituent of plasma cell membrane of all the 
cells and also present in myelin sheath of nervous cell. (7),(8)  
 
 Cholesterol is the precursor of all the steroid hormones, glucocorticoids, 
mineralocorticoids, androgens, estrogens, progesterone, bile acids and vitamin D. 
(5), (9) 
 
 Statins by inhibiting cholesterol synthesis may affect normal plasma 
membrane function of many cell types and may produce chronic muscle pain, 
fatigue, joint pain, numbness, memory problems, mood disorders, depression, 
sleep disturbance, impaired immune function and impotence.  
 
 Coenzyme-Q is a important component of electron transport chain in 
mitochondria which is important to produce energy in the form of ATP and it is a 
key mitochondrial anti oxidant. Statins by inhibiting Coenzyme-Q production may 
produce myalgia, chronic fatigue syndrome, hypertension, and 
cardiomyopathy.(10) 
         
 Since both cholesterol and co enzyme Q production is inhibited by statins 
these may produce various adverse effects. (1) 
 Fatty liver (or) hepatic steatosis is an abnormal accumulation of fat in liver 
cells. (11) 
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 Fatty liver changes commonly found in patients taking statins for long 
duration. Statins by inhibiting cholesterol synthesis may produce fatty liver 
changes.(12) 
 Fatty acid synthesis occurs primarily in the liver by conversion of Acetyl-
coA to malonyl coA, mediated by the enzyme Acetyl coA carboxylase . Malonyl 
coA is the precursor for the Fatty acid synthesis. 
 
 Inhibition of the enzyme HMG coA reductase results in accumulation of 
Acetyl coA in the liver. This increase the synthesis of enzyme Acetyl coA 
carboxylase (ACC) resulting in increased fatty acid synthesis in the liver. (13) 
 
 Individuals with fatty liver changes are usually asymptomatic at initial 
stages, but this may progress to Non alcoholic steatohepatitis (NASH) , Cirrhosis, 
Decompensated liver disease (DCLD) and Hepato cellular carcinoma at later 
stages.(11) 
 
 Fatty liver is commonly associated with conditions like alcoholism, 
diabetes, obesity, dyslipidemia, Wilson’s disease, hepatitis. 
 
 Glucocorticoids, amiodarone, tetracycline, Valproic acid, tamoxifen, 
methotrexate, indinavir are some common drugs causing fatty liver. Drug induced 
fatty liver mostly resolves once the offending drug is stopped.(14) 
 
         This study will look for the prevalence of fatty liver in patients taking tablet 
Atorvastatin. This will help to restrict the use of statins in liver disease and to 
include fatty liver in the adverse drug profile of statins. 
Review of Literature 
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REVIEW OF LITERATURE 
 
PHYSIOLOGY OF LIPIDS 
               Lipids are physiological substances which are hydrophobic and non 
polar which contributes around twenty percent of body weight. They are the main 
storage form of energy in our body and also have a role in cellular structure 
formation and helps in various biochemical functions. (15) 
 
CLASSIFICATION OF LIPIDS 
Simple lipids 
They are esters of fatty acid with alcohol;  (E.g)  Oil and fat 
They are esters of fatty acid with Glycerol.  
Esters of fatty acid with alcohol other than glycerol are called Waxes. 
 
Complex lipids   
 Otherwise called compound Lipids and they are esters of fatty acid with 
alcohol along with some additional groups like carbohydrate, protein, phosphate 
or nitrogenous base. (E.g) Phospholipids 
 
 Along with Fatty acid and Alcohol it contains Phosphoric acid and a 
nitrogenous base.      
 
Glycolipid 
 They contain Fatty acids, carbohydrates and Nitrogenous base. They are 
otherwise called Glycosphingolipids.  
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 Cerebrosides and Gangliosides are examples of it. 
 
Lipoprotein 
 They are the complex of Lipids and Proteins. 
 
Derived lipids 
 They are derivatives of simple and complex lipids by hydrolysis. 
(E.g)  Ketone bodies, Steroid hormones. (16) 
 
Structure of fatty acids, TAG, complex and derive lipids 
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FATTY ACIDS 
 Fatty acids are the simplest form of lipids. Chemically they are carboxylic 
acids with hydrocarbon side chain. it has hydrophobic hydrocarbon and a terminal 
carboxyl group which has affinity for water. This makes the Fatty acid 
Amphipathic that means Fatty acids are both Hydrophilic and Hydrophobic in 
nature. 
 
 They commonly present in esterified form in our body, when it is present 
as un esterified form they are called free fatty acids. (13) 
 
SATURATED FATTY ACIDS 
 The hydrocarbon chain of Fatty acids with no double bond in its structure 
is called saturated Fatty acids. High intake of saturated fat has high association of 
increased total plasma cholesterol level and increased risk of coronary heart 
disease.  
 
 Saturated fatty acids with 16 and 14 carbons have more potency to increase 
serum cholesterol level. 
 
 Major source of saturated fatty acids are meat, dairy products, vegetable 
oils like palm oil and coconut oil. (Eg) Butyric acid,  Propionic acid.        
 
MONOUNSATURATED FATTY ACIDS 
 They are primarily the Fatty acids with one Double bond in its structure. 
They are mainly present in vegetable oils like olive oil and fish. 
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              When these monounsaturated fatty acids (MUFAs) substituted in diet for 
saturated fatty acids, it reduces serum cholesterol and LDL cholesterol levels and 
maintains or elevates HDL cholesterol.  
 
POLYUNSATURATED FATTY ACIDS 
             Fatty acids with more than one double bond in its structure are called 
Polyunsaturated Fatty acids (PUFAs). The location of double bond in the Fatty 
acid chain is important factor for its influence in heart disease.        
 
W6 Fatty acids  
 They are polyunsaturated Fatty acids which has first double bond in sixth 
position when counting from methyl end of the fatty acid chain. It is commonly 
present in vegetable oils and nuts, olives, soybean, corn oil.  
 
 It lowers plasma cholesterol levels along with lowering LDL level; but 
HDL levels also lowered.  
 
W3 Fatty acids 
 They are the PUFAs with first double bond at third position of fatty acid 
chain when counting from methyl end. 
 
 Dietary supplementation of w3 fatty acids have little effect on serum LDL 
and HDL levels but it lowers blood pressure, cardiac arrhythmias, decrease 
tendency of thrombosis and overall it reduces cardiovascular mortality. 
(Eg) .Linolenic acid, Docosahexaenoic acid (DHA) , Eicosapentaenoic acid . 
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TRANS FATTY ACIDS 
               In naturally occurring Unsaturated Fatty acids, Hydrogen bond on the 
carbon atom which participate in double bond formation present in the same side 
of the fatty acid chain which is called cis isoform; this cis form makes the chain to 
bend ; so more number of double bond makes fatty acids to bend more and makes 
it flexible.  
 
 Commercially Hydrogenation is used to solidify the liquid form of 
unsaturated fatty acids.  This is mainly used in Frying Fats , snacks, baked foods. 
This hydrogenation makes Trans isoform of fatty acids where hydrogen bond 
present both side of the fatty acid chain.  
 
 Normally cis form of unsaturated fatty acids present in phospholipids of 
plasma membrane which makes the membrane flexible and maintains the fluidity.  
 
 If Trans form of fatty acids packed in membrane, it will not bend and 
makes the cell membrane rigid and affects its fluidity and normal physiological 
function. Clinical studies suggested that high intake of Trans Fatty acids 
associated with increased risk of coronary heart disease, diabetes mellitus and 
cancer. 
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ESSENTIAL FATTY ACIDS 
 Fatty acid which cannot be synthesised in the body and the diet is the only 
possible source of it is called Essential Fatty acids. Humans lack the enzymes to 
produce double bond beyond 9th or 10th carbon in fatty acid synthesis. So these 
essential fatty acids cannot be produced.  
 
            They are actually polyunsaturated fatty Acids, which required for 
membrane structure formation and its function, and synthesis of Eicosanoids. 
Prostaglandins, prostacyclins, Leukotrienes, Lipoxins and Thromboxanes are 
called Eicosanoids. 
 
 Deficiency of essential fatty acids leads to phrynoderma. (Eg)  linoleic 
acid, Iinolenic acid and Arachidonic acid - it becomes essential only when linoleic 
acid not available in the diet.(17) 
 
LIPID METABOLISM   
Dietary lipid metabolism 
 Average adult dietary intake of fat in US population is around 80g, of that 
more than 90 percent is in the form of triacyl glycerol (TAG) and the other types 
are cholesterol, cholesterol esters, free fatty acids and phospholipids.(18)  
 
 Digestion of exogenous dietary lipids begins in the stomach by lingual and 
gastric lipase enzymes but pancreatic enzymes are having important digestive 
role. Pancreatic lipase degrades TAG and cholesterol esters hydrolysed by 
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cholesterol esterase. Dietary cholesterol which is present in the free form is 
absorbed directly. 
 
 Bile salts which are derivatives of cholesterol is synthesised in liver and 
stored in gall bladder is secreted to intestinal fat and emulsify it and makes the fat 
more easily absorbable. 
         
 The products of intestinal lipid digestion are fatty acids, free cholesterol, 2-
mono acyl glycerol and fat soluble vitamins. This mix along with bile salts and 
form mixed micelles and are absorbed in the brush border of intestinal cells 
mainly in ileum. But short and medium chain fatty acids are water soluble so 
easily absorbed without micelles formation.  
 
 The intestinal cells re synthesize TAG along with Apolipoprotein-B48 , 
these are assembled together and form chylomicrons. chylomicrons are formed by 
lipids surrounded by cholesterol, phospholipd and ApoproteinB-48. These are 
released into blood circulation through lymphatic duct.  
 
 Chylomicrons circulating in blood metabolised by an enzyme  called 
Lipopropein lipase. This enzyme is mainly present in the capillary endothelium of 
muscle and adipose tissue. Lipoprotein lipase degrades TAG to free fatty acids 
and glycerol. 
 
 Many tissues in our body can utilise the Free fatty acid for energy 
production but adipose tissue can re esterify this fatty acid to triacyl glycerol and 
store it. 
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           Glycerol released from TAG is converted to glycerol-3-phosphate in liver 
and enters glycolysis . After TAG is released from chylomicron , it is called 
chylomicron Remnants which contains small amount TAG and cholesterol esters 
phospholipids . this is taken  by liver cells for further metabolism. 
 
FATTY ACID METABOLISM 
 Fatty acids present in our body as free unesterified form or esterified form 
such as Triacylglycerol (TAG). fatty acids present in plasma as free form mainly 
transported by Albumin from the site of origin to consumption like Liver , skeletal 
muscle and cardiac muscle. 
 
               Fatty acids present in phospholipids and glycolipids help in formation of 
cell membrane. And some fatty acids are precursors of prostaglandins also. 
 
ENDOGENOUS SYNTHESIS OF FATTY ACID 
 A major part of Fatty Acids used by our body is derived from Diet but 
when carbohydrate and proteins obtained from diet in excess of our body needs 
can be converted to Fatty acids and stored as Triacylglycerol. This endogenous 
Fatty acid synthesis occurs in cytoplasm mainly in Liver and lactating Mammary 
Glands and some extent in Adipose tissue. 
 
 In the process of fatty acid synthesis Acetyl coA ( coA) donates carbon 
units, Adenosine triphoshate (ATP) gives energy, and reducing equivalents 
provided by Nicotinamide Adenine Dinucleotide Phosphate(NADPH). Acetyl 
coA formed from Pyruvate which is a product of glycolysis in mitochondria. The 
12 
 
initial step in Fatty acid synthesis is transfer of Acetyl coA from mitochondria to 
cytosol. 
 The Acetyl  portion in Acetyl coA can cross the mitochondrial membrane 
but the CoA portion cannot cross it but condensation of oxaloacetate and acetyl 
coA forms citrate in mitochondria and this citrate can easily cross the membrane 
and reaches cytoplasm where it can reform oxaloacetate and Acetyl coA. This is 
how Acetyl coA reaches cytosol and increased presence of citrate and ATP 
enhances Fatty acid synthesis.  
 
               The next step is carboxylation of Acetyl coA which forms malonyl coA 
and this step is catalysed by Acetyl coA Carboxylase (ACC). This rate limiting 
step in Fatty acid synthesis needs ATP , Carbondioxide ( co2) and Biotin.  
 
 ACC enzyme activity is enhanced by insulin which dephosphorylate the 
enzyme and activates it. High intake of diet rich in calories and carbohydrate also 
stimulate ACC enzyme. All these factors leads to increased production of fatty 
acid whereas Adrenaline and Glucagon phosphorylate the enzyme ACC and 
decrease the production of Fatty acids. Long chain fatty acids, low calorie and 
high fat diet leads to decreased Fatty acid production. 
 
 Malonyl coA donates 2 carbon unit in every cycle of reaction which is 
repeated 5 more times into the growing fatty acid chain at the carboxyl end. The 
fatty acid reaches a length of 16 carbons, the process is terminated releasing a 
fully saturated molecule of Palmitate (16:0). 
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         In mammary gland Shorter length fatty acids are formed as an important end 
product, but in Brain very long chain fatty acids that of more than 22 carbons are 
formed for the synthesis of brain structural lipids. 
 
Mechanism of action of Acetyl CoA Carboxylase ( ACC ) 
 
 
Storage of fatty acids 
            Three Fatty acids are esterified through carboxyl end to one molecule of 
Glycerol and forms Triacylglycerol (TAG). TAG is less water soluble and it is 
stored as lipid droplets in cytoplasm of adipocytes. Liver also stores small portion 
of TAG; but major part of TAG formed in liver is transported to peripheral tissues 
along with Apoprotein as VLDL. 
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        Glycerol phosphate is the acceptor of Fatty acids in TAG synthesis. It is 
derived from two ways. One is from Glycolysis, where glucose is metabolised to 
Dihydroxyacetonephosphate (DHAP) and DHAP reduced to Glycerol Phosphate 
by the enzyme Glycerol phosphate dehydrogenase. Second pathway is convertion 
of Glycerol to Glycerol Phosphate by the enzyme Glycerol kinase. (16) 
 
Fatty acid oxidation 
 Fatty acid in the form of TAG stored in adipose tissue and it is the major 
energy reserve for the body. When the body needs Fatty acids as energy source, 
particularly during starvation and type 2 diabetes mellitus, the stored TAG used 
for energy production. 
 
 TAG gives high amount of metabolic energy since they are present in 
highly reduced form. Complete oxidation of fatty acid yields CO2 and H2O and 9 
Kcal/ G of Fat whereas protein and carbohydrates yields 4Kcal/G only.  
 
 Release of free fatty acids and Glycerol is catalysed by an enzyme called 
Hormone sensitive Lipase ( HSL). This enzyme removes Fatty acids from carbon 
1 and carbon 3 of TAG. Further release of Fatty acids catalysed by Lipase enzyme 
specific for Diacylglycerol and Monoacylglycerol. 
           
 Hormone sensitive Lipase (HSL) enzyme is activated by Phosphorylation 
by cAMP dependant Protein Kinase.  Epinephrine and Glucagone activates HSL 
enzyme and promotes the breakdown of TAG. Insulin and increased serum 
Glucose inactivates the enzyme HSL and decreases TAG breakdown.  
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Regulation of Hormone sensitive Lipase (HSL) by insulin and Epinephrine 
 
 
Fate of glycerol 
               Glycerol released from TAG cannot be metabolised by Adipocytes since 
they do not have the enzyme Glycerol Kinase. So it is transported to liver then 
Phosphorylated to Glycerol Phosphate.  
            This Glycerol Phosphate can be used by Liver for TAG production or it 
can be converted to DHAP by Glycerolphosphate Dehydrogenase. This DHAP 
can participate in Glycolysis or Gluconeogenesis.  
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Fate of free fatty acids 
 Free Fatty acids formed in adipose tissue is bound to plasma Albumin and 
transported to Liver and various organs like skeletal muscle and cardiac muscle. 
 
 In Liver FFAs are converted to TAG and transported with VLDL to 
peripheral tissues. 
 
 In cardiac and skeletal muscle FFAs are used for energy production, 
whereas RBCs cannot use FFA for energy production since it does not have 
mitochondria. 
 
 Brain also does not use FFAs for energy but the reason is not clear. (20) 
 
BETA OXIDATION OF FATTY ACIDS 
 Free fatty acids mainly oxidised by mitochondrial pathway and it is called 
Beta oxidation. In Beta oxidation two carbon compounds successively cleaved 
from carboxyl end of fatty acid and produces Acetyl coA, NADH and FADH2.  
 
Fatty acids are of four types depending on the length, they are  
1. Short chain fatty acids 
2. Medium chain fatty acids 
3. Long chain fatty acids (LCFA).  
4. Very long chain fatty acids.  
 
 Short and medium chain fatty acids (less than 12 carbons) do not require 
any specific form of transport mechanism to enter into mitochondria.  But long 
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chain Fatty acids cannot cross the inner mitochondrial membrane and a 
specialised transport mechanism is required and it is called Carnitine Shuttle.  
 
 Carnitine shuttle is the rate limiting step in LCFA oxidation. Further steps 
in Beta oxidation metabolised by a group of enzyme called Acyl coA 
dehydrogenase. 
 
 Beta oxidation is a cyclic reaction and every cycle has sequence of 4 
reactions. The first one is Oxidation that produce FADH2 and the second one is 
Hydration; third step is the formation of NADH; fourth step is release of Acetyl 
coA. These steps are repeated till the Fatty acid is completely oxidised.  
 
 Oxidation of fatty acids produce high amount of energy. One molecule of 
Palmitoyl coA produces 8 acetyl coA; 7 NADH; 7 FADH2 and it can generate 
131 ATP. Since 2 ATP required for the activation of Fatty acid, the net yield is 
129 ATPs. 
 
CHOLESTEROL METABOLISM 
 Cholesterol is a steroid alcohol of animal tissues and it has many vital 
functions in the body like it is the structural component of all the cell membranes; 
and maintains its fluidity. 
 
 Cholesterol is the precursor of steroid hormones, sex hormones, Vitamin D 
and Bile acids. (21) 
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 Liver plays the central role in the body’s cholesterol homeostasis.(22) It 
maintains the balance between de novo synthesis of cholesterol and excretion 
of cholesterol through bile acids. (23) 
 
 Cholesterol is hydrophobic in nature and it has four hydrocarbon ring fused 
to form Steroid nucleus, and it is the main sterol in animal tissues. 
 
 In plasma cholesterol present as a esterified form in which Fatty acids are 
attached to it are called Cholesterol esters (CE).This cholesterol esters are more 
hydrophobic than cholesterol, so in plasma it can be transported in bound form 
with Lipoproteins.  (24) 
 
Structure of Cholesterol and Cholesterol esters 
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Cholesterol synthesis 
 Cholesterol can be synthesised by all the tissues in the body but Liver, 
Adrenal glands, Ovaries, Testes, Intestine are the main contributions in body’s 
cholesterol pool. 
 
 In the process of cholesterol synthesis, all the carbon atoms are provided 
by Acetate and reducing equivalants are provided by NADPH.it needs enzymes in 
both cytosol and Smooth endoplasmic reticulum (ER).  This endogenous 
cholesterol synthesis is responsible for bodies cholesterol concentration, any 
imbalance in the regulatory mechanism of this pathway leads to increased plasma 
concentration of cholesterol. 
  
 The first two steps in cholesterol synthesis are similar to the pathway in 
ketone body production. Two acetyl coA molecules condense and forms 
Acetoacetyl coA, and with this a third molecule of Acetyl coA is added and HMG 
coA formed; this reaction is catalysed by HMG coA synthase . 
 
 HMG coA synthase enzyme has two isoforms. One is present in the cytosol 
which helps in cholesterol synthesis; and the other one is present in the 
mitochondria which help in the formation of Ketone bodies.  
 
    In the next step HMG coA is reduced to Mevalonate by the enzyme HMG 
coA Reductase . it is the rate limiting step in cholesterol synthesis. This is the 
irreversible reaction takes places in cytosol and it requires two molecules of 
NADPH as reducing agents. 
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Synthesis of HMG coA from Acetyl coA 
 
 
 In the next following steps converts mevalonate to Isopentyl 
pyrophosphate (IPP) and this IPP is the precursor for Isoprenoid family. Dolichol 
and Ubiquinone is non steroid Isoprenoids. 
 
 IPP forms Lanosterol and finally Lanosterol are converted to cholesterol 
and these are multi site processes.  
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Action of HMG coA reductase 
 
 
Regulation of cholesterol synthesis 
 HMG coA  Reductase is the rate limiting enzyme and it is regulated by 
many factors.  
 
 If the Sterol level in the cell is low it stimulates Sterol regulatory element- 
binding protein (SREBP) which binds to Strerol regulatory element (SRE) and 
acts as a transcription factor and increases the synthesis of HMG coA reductase 
enzyme and increase cholesterol synthesis; and when sterol level is high , HMG 
coA reductase is decreased and cholesterol synthesis also decreased.  
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 Increase in insulin and Thyroxine up regulates the gene for the enzyme 
HMG coA reductase and increases cholesterol production; whereas Glucagon and 
Glucocorticoids down regulates the enzyme and decreases cholesterol production. 
 
Degradation of cholesterol 
 The ring structure or the sterol nucleus of cholesterol cannot be 
metabolised in humans; so it is converted to bile acids and bile salts which are 
eliminated through feces.  
 
 Bile is a mixture of organic and inorganic compounds; Phosphatidylcholine 
and bile salts are important organic compounds present in bile. Bile is formed in 
Liver and can directly enter Duodenum or it can be stored in Gall bladder and 
secreted when it is needed. 
 
 The bile acids are amphipathic and the molecules have both polar and non 
polar face; it can acts as an emulsifying agent in the intestine and helps to prepare 
the dietary complex lipids and Triacylgylcerol for degradation by pancreatic 
Lipase. 
 
 Bile acid synthesis is a multi step process in liver by which the primary bile 
acids Cholic acid and Chenodeoxycholic acid formed. The rate limiting step in 
bile acid synthesis is catalysed by the enzyme cholesterol-7-a-hydroxylase. 
 
 In liver the primary bile acids are conjugated with glycine or taurine and 
forms glycocholic and glycochenodeoxycholic acids, and taurocholic and 
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taurochenodeoxycholic acids. These conjugated forms are fully ionised at 
physiological PH and are called bile salts. These bile salts are more amphipathic 
and more effective detergents. 
            
 In intestine bacteria can remove taurine and glycine from bile salts and 
regenerates bile acids. They can also form secondary bile acids – deoxycholic acid 
and lithocholic acid from primary bile acids.  
 
 95% of bile salts secreted in intestine actively reabsorbed mainly in the 
ileum and taken back into Liver and re secreted in bile, this continuous process is 
called enterohepatic circulation. Around 15 to 30 grams of bile salts are secreted 
into duodenum by liver everyday but 0.5 gram only eliminated in the feces. (25) 
 
PLASMA LIPOPROTEINS 
 Lipoproteins are the spherical macromolecule complex of Lipids and 
Apoproteins. They are of four types, Chylomicrons (CM), Very low density 
lipoproteins (VLDL), Low density Lipoproteins (LDL), and High density 
Lipoproteins (HDL). These lipoproteins differ in their lipid and protein content, 
density, site of origin and size. 
 
 The main function of lipoproteins in plasma is to keep the lipids soluble 
and transports the lipids to and from the tissues.  
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Structure of plasma Lipoproteins 
 
 
Composition of lipoproteins 
           Lipoproteins made up of neutral lipid core which contains TAG and 
Cholesterol esters. It is surrounded by Amphipathic Apolipoproteins, Free 
cholesterol and phospholipid; and this amphipathic nature makes it water soluble. 
Cholesterol esters and TAG are either obtained from diet or endogenous source.  
            
         Chylomicrons are largest in size and having lowest density and having 
highest percentage of lipids and lowest protein. VLDL and LDL are successively 
densier and HDL is densest.  
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 Apolioprotein present along with Lipoproteins provides many function like 
it is the recognition site for cell surface receptors; it also functions as activator or 
coenzyme for enzymes participates in Lipoprotein metabolism. They are mainly 
divided into five classes- A, B, C, D, E and they have subclasses.  
         
Metabolism of chylomicrons 
 Chylomicrons are formed in intestinal mucosa and carries TAG, 
Cholesterol, cholesterol ester, lipid soluble vitamins to peripheral tissues.  
 
 Apolipoprotein B-48 synthesised in rough endoplasmic reticulum in 
intestinal cells and they are unique to chylomicrons but TAG, cholesterol, 
cholesterol esters, phospholipids are synthesised in smooth endoplasmic 
reticulum. Assembly of this lipids and Apo-B48 is done by Microsomal 
Triacylglycerol transfer protein (MTP), and then they are packed in a secretory 
vesicle and released. 
 
 The chylomicron released is called nascent chylomicrons which is 
functionally incomplete. In plasma Apo E and Apo C-II are added; Apo-CII is 
necessary for the enzyme Lipoprotein lipase activation.  
          
 Lipoprotein lipase is an extra cellular enzyme attached to capillary 
endothelium in many tissues; particularly Adipose tissue, cardiac and skeletal 
muscle. This enzyme is activated by Apo C-II and it degrades TAG to Fatty acids 
and Glycerol. These fatty acids are taken up for energy in muscles and stored in 
adipose tissue. Glycerol used by liver for gluconeogenesis. 
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             Lipoprotein lipase enzyme activity is increased by Insulin. Km value of 
this enzyme differs at different sites. Cardiac muscles have this enzyme in high 
concentration and Km value is low which makes the fatty acids to be available for 
cardiac muscle even when the plasma concentration is low.  
 
            After TAG is metabolised by the enzyme lipoprotein lipase, the remaining 
chylomicrons are called remnants which is rapidly taken up by Liver from 
circulation by endocytosis. Apo C also returned to HDL. After taken up by liver, 
this Chylomicron remnants are fused with Lysosomes and degraded to form 
Amino acids, Fatty acids and free Cholesterol.  
 
Metabolism of VLDL 
 VLDL is produced by Liver; it composed mainly of endogenously 
synthesised TAG and main function of this VLDL is to transport the Lipids from 
Liver to peripheral tissues.  
 
             Nascent VLDL is secreted into circulation and it contains Apo B-100; and 
after that it obtains Apo C-II and Apo E from HDL. In circulation TAG present in 
VLDL is degraded by the enzyme Lipoprotein Lipase makes VLDL denser; Apo 
C II and E returned to HDL. These modifications convert VLDL to LDL; But 
during this transition Intermediate density  
 
 Lioproteins(IDL) are observed. These IDL also can be taken up by receptor 
mediated endocytosis in liver. 
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Metabolism of LDL 
 LDL has less amount of TAG and high concentration of cholesterol than 
VLDL since TAG is removed by Lipoprotein lipase. The main function of LDL is 
to deliver Cholesterol to peripheral tissues. 
 
 LDL binds to cell surface membrane receptor and it is mainly recognised 
by Apo B-100. After binding, LDL receptor complex endocytosed and inside the 
cell these vesicles fuse with other similar vesicles to form large Endosomes.  
 
 Inside the cell vesicle, LDL and the receptors are separated and the 
receptors are recycled; the remaining LDL containing vesicle transferred to 
lysosome where it is degraded by the enzyme Acid hydrolase and gives 
Cholesterol, phospholipid, Amino acid and fatty acid. 
 
 The endocytosed Cholesterol inside the cell, inhibits HMG coA reductase 
and decreases endogenous cholesterol synthesis. It also decreases new LDL 
receptor formation thereby decreases the further entry of LDL attached cholesterol 
inside the cell. If the cholesterol inside the cell not required for utilisation, it is 
esterified to cholesterol esters by the enzyme Acyl coA:Cholesterol 
acylytransferse (ACAT) and stored inside the cell.  
           
 The lipid component or the Apo B present in the LDL may get oxidised 
and produce chemically modified LDL. This is taken up by macrophages by 
Scavenger receptor type A and this leads to accumulation of cholesterol inside 
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macrophage. It is called Foam cells and this participates in Atherosclerosis 
formation. 
 
HDL metabolism 
 HDL metabolism is complex and not completely understood. HDL is 
formed in blood by Lipids and Apo A-1. Apo A-1 if formed in liver and intestine 
and secreted to circulation.  
 
 HDL has many functions like it is the reservoir of Apo C-II which 
transferred to VLDL and chylomicron and activates the enzyme Lipoprotein 
lipase, and Apo E which required for receptor mediated uptake of IDL and 
chylomicron remnants. The nascent HDL has more amount of Phospholipid and 
Apo A, C, E. they take up the cholesterol from peripheral tissues and return it to 
liver as cholesterol esters.  
 
 HDL takes up the cholesterol and esterifies it to cholesterol esters by the 
enzyme lecithin:cholesterol acyl transferase (LCAT). This LCAT is secreted by 
liver and activated by Apo A-1.  
 
 Transfer of cholesterol from peripheral tissues to liver is done by HDL; and 
in liver cholesterol is used to synthesise bile acids and excreted. HDL also 
transfers cholesterol to steroidogenic cell for hormone synthesis. This process is 
called Reverse Cholesterol transport thus HDL is considered as good cholesterol. 
The efflux of cholesterol is done by a transport protein called ABC 1. The uptake 
of HDL by liver is mediated by scavenger receptor B 1. (26) 
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STEROID HORMONES 
            All types of steroid hormones synthesised from cholesterol only. 
Glucocorticoids, mineralocorticoids, Androgens, Estrogens, progestins are 
secreted from organs like adrenals, ovaries, testes and placenta. Since steroid 
hormones are synthesised from cholesterol, they are hydrophobic and transported 
in blood by plasma proteins only. 
 
 Steroid hormone synthesis occurs in mitochondria with the help of 
cytochrome P450 mixed function oxidase. The rate limiting step is conversion of 
cholesterol to 21 carbon pregnenolone and important control point in steroid 
synthesis is movement of cholesterol into mitochondria.  
 
 Pregnenolone is the precursor for all other steroid hormones from which all 
other hormones synthesised.  
 
 Cortisol is produced from middle layer of adrenal cortex in response to 
stress. Cortisol manages body’s stress by mechanisms like Gluconeogenesis, 
inflammatory and immune responses. 
 
 Aldosterone is produced by outer layer of adrenal cortex in response to 
decreased plasma sodium potassium ratio and by Angiotensin II. It mainly acts in 
renal tubules and increases sodium uptake and promotes potassium excreation.  
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 Androgens are secreted by inner and middle layer of adrenal cortex. 
Mainly dihydroepiandrosterone and androstenedione are formed. They are 
converted to testosterone and then as estrogen in periphery.  
 
 Testes and ovary produces the sex hormones like estrogens, progesterone 
and testosterone which is necessary for sexual differentiation and reproduction.  
 
 All these steroid hormones acts in the target cells by diffusing across the 
cell membrane and bind to a cytosolic or nuclear receptor. This further binds to 
specific DNA regulatory sequence and causes alteration in transcription.(27) 
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THE LIVER  
 The liver is a large solid soft gland in the body which is situated in the right 
upper quadrant of the abdominal cavity. The average weight of liver in male is 
1600 g and it is 1300 g in female. It is divided into two lobes, the right and the left 
lobe, five surfaces – anterior, posterior, superior, inferior and right surface. 
 
 The right lobe is larger than the left lobe and it forms 5/6th of the liver, left 
lobe forms 1/6th of the liver. Liver gets its 20% of the blood supply from hepatic 
artery and the remaining 80 % is by portal vein. Venous drainage is through 
hepatic veins which drain into inferior vena cava (IVC). (28) 
 
Functions of liver 
 The liver is important visceral organs which uniquely situated and 
performs many complex inter relating functions of the body. It processes and 
distributes dietary nutrients absorbed from gut. During the absorptive period, liver 
takes up the carbohydrates, lipids and amino acids and they are metabolized, 
stored and distributed to other organs.  
 
 Carbohydrate metabolism 
 Glucose uptake from dietary source by the hepatocytes is not rate limiting 
because of GLUT-2 glucose transporter which is insensitive for insulin.  
 
 The glucose is converted to Glucose 6 phosphate is either converted to 
glycogen or undergoes glycolytic metabolism. 
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 Glucose is converted to Acetyl coA in the presence of insulin which is used 
as building block for fatty acid synthesis or provides energy by oxidation in TCA 
cycle. 
 
 Liver also converts galactose and fructose to glucose. 
 Gluconeogenesis – forms glucose from non-carbohydrate sources 
 
 Fat metabolism  
 Liver is a primary tissue for the synthesis of fatty acids which occurs in 
absorptive period when dietary calorie intake is high. 
 
 Acetyl coA and NADPH derived from glucose metabolism forms the 
substrates for fatty acid synthesis. 
 
 Liver synthesis lipoproteins like VLDL, LDL and HDL. 
 
 Liver has an important role in the regulation of body’s cholesterol 
homeostasis. Cholesterol enters the liver from dietary sources as well as 
synthesized from extra hepatic tissues and by liver. 
 
 Cholesterol is transported to peripheral tissues along with TAG through 
VLDL 
.  
 Free cholesterol is eliminated in the bile as such or converted to bile acids 
or bile salts. 
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 Protein metabolism  
 Synthesis of plasma proteins like Albumin 
 
 Steroid and other hormone binding protein. 
 
 Liver helps in inter conversion of many amino acids and synthesis of other 
compounds from amino acids. 
 
 Liver performs deamination reaction of amino acids 
 It removes ammonia from body by forming urea. (29) 
 
Liver in fasting 
 The main function of liver during fasting is to maintain the blood glucose 
level.  
 
 During fasting due to decreased insulin level and increased glucagon level, 
the enzyme glycogen phosphorylase is phosphorylated and it causes rapid 
conversion of glycogen to glucose. 
 
 After liver glycogen stores are depleted during prolonged fasting, blood 
glucose level is maintained by glycerol and amino acids by gluconeogenesis.  
 
 Hydrolysis of adipose tissue produces high amount of fatty acids during 
fasting. This fatty acids undergoes oxidation to produce energy. 
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 Ketogenesis occurs during fasting when concentration of Acetyl coA 
produced during fatty acid oxidation exceeds the oxidative ability of citric acid 
cycle.  
 
 During fasting rapid breakdown of proteins in muscle provides amino acids 
and they are used by the liver in gluconeogenesis. Alanine and glutamine are the 
important gluconeogenic amino acids. 
 
Interrelationship between Carbohydrate, Protein and Fat Metabolism 
 
                                   GLUCOSE METABOLISM (GLYCOLYSIS)  
Protein metabolism                                                                 fat metabolism 
 
   KETONE BODIES                   ACETYL COA                   FATTY ACID 
                 CHOLESTEROL 
TCA CYCLE 
 
ATP+H2O+CO2 
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Interrelationship between Carbohydrate, Protein and Fat Metabolism 
 
 
 
 Liver also store many vitamins like vitamin A, D and B12 
 
 Next to haemoglobin, liver is the organ to store large proportion of iron in 
the form of ferritin. 
 
 Liver forms many clotting factors like fibrinogen, prothrombin, clotting 
factors VII, IX and X. Vitamin K is required for the synthesis of above mentioned 
clotting factors 
 
 Liver detoxifies and excrete many drugs including penicillin, ampicillin, 
erythromycin and sulphonamides. 
 
 Several hormones secreted by endocrine glands are metabolized and 
excreted by liver. (Eg)  Thyroxine, Steroid hormones.  
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 Calcium also excreted by liver through bile.  
 
 Liver normally secretes 600-1000 ml of bile per day. This bile has an 
important role in dietary fat digestion. Bile acids present in the bile helps to 
emulsify the large fat particles present in the food and makes into minute 
particles, which then can be metabolized by pancreatic lipase enzyme.  
 
Bile helps in excretion of many waste products from the body which 
includes the end product of hemoglobin destruction – Bilirubin. 
 
Liver also excretes excessive cholesterol through bile.  
 
DRUG INDUCED LIVER INJURY (DILI)  
            The liver is the principal organ for metabolism of foreign substances. Both 
liver and kidney are responsible for excretion of chemicals and drugs from the 
body. Generally highly water soluble and low molecular weight drugs excreted by 
kidneys whereas High lipophilic and high molecular weight drugs metabolised by 
liver. 
 
          DILI is the major toxic adverse effect of drugs and Hepatotoxicity is the 
reason for many drugs to be withdrawn from the market. The reasons for DILI are 
not fully known and it is difficult to confirm the diagnosis of DILI because no test 
is available to confirm that the given drug in a given individual is responsible for 
the liver injury.  
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The following factors are believed to be involved in DILI. 
o Drug - class, duration, dose. 
o Host – age, gender, genetic factors, BMI 
o Environment – diet, other toxins, anti oxidants. 
 
 The clinical manifestation of DILI varies from asymptomatic laboratory 
abnormality to severe life threatening condition like acute or sub acute liver 
failure. Whenever the drug induced liver injury is suspected, the culprit drug 
should be discontinued unless it is impossible to do it in a safe manner.     
 
Epidemiology 
 The common and well known drugs causes of DILI are Paracetamol, 
sodium valproate, Phenytoin, Isoniazid and Prophylthiouracil. But all these drugs 
are commonly used and available in the market because of the benefit outweighs 
the risk.  
 
 In the year between 1990 to 2002 acute liver failure from the above 
mentioned drugs were responsible for 15% of all liver transplantations.  (30) 
 
Clinico pathologic patterns of DILI 
Cholestasis  
Interference with the flow of bile by drugs causes cholestasis.  
(e.g)Oestrogen, Oral contraceptive pills. 
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Hepatocellular injury or hepatocyte necrosis  
 It is manifestated by acute hepatocellular necrosis with high serum 
transaminase concentration. (e.g) Paracetamol , Diclofenac , Isoniazid  
 
Steatosis 
 Due to direct effect on mitochondrial beta oxidation there will be 
microvesicular fat deposition in hepatocytes. (E.x) tetracyclines, sodium 
valproate.  
 
 Macro vesicular fat deposition is associated with Tamoxifen and 
Amiodarone. 
 
Vascular and sinusoidal lesions 
 Drugs like Alkylating agents can damage the vascular endothelium in the 
liver which can lead to hepatic venous outflow obstruction.  
 
 Vitamin A toxicity can damage the hepatic sinusoids and promotes the 
fibrosis and portal hypertension.  
 
Hepatic fibrosis 
 Most of the hepatotoxic drugs produce reversible cell injury and fibrosis 
does not occur. But some drugs like methotrexate when used for long duration can 
leads to hepatic fibrosis. (31) 
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DILI due to statins 
 Statins are one of the most widely prescribed drugs for a long term. The 
exact mechanism of liver injury due to statins are not known but few studies have 
shown that toxicity is mainly due to inhibition of HMG CO A REDUCTASE and 
MEVALONATE SYNTHESIS since it is the important pathway for the 
production of cell membrane and steroids. 
 
 Statins are mainly metabolised by Cyp3A4 and many drugs like 
Ketoconazole, Verapamil, Gemfibrozil, Niacin, Amiodarone are interacts with its 
metabolism and produces toxicities.  
            
 The most common pattern of liver injury is Hepatocellular type with the 
elevation of liver enzyme ALT ranges from 39 to 8275 IU/L. 
 
 Mixed hepatocellular and cholestatic liver injuries can also occur with 
statin.On liver biopsy portal inflammation with mononuclear cells infiltration with 
or without cholestasis is the most commonly found histological feature in DILI 
due to statins. (32) 
 
FATTY LIVER  
 Fatty liver (or) hepatic steatosis is intracellular accumulation of neutral fat 
in the cytosol of hepatocytes. 
 
 Liver is the most common site for fatty changes because it plays a central 
role in lipid metabolism.  
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 Depending on the amount of the fat accumulated and the cause of fatty 
liver, it may be mild and reversible (or) it may be severe and produce irreversible 
changes.  
 
Causes of fatty liver  
 Conditions with excessive fat like  
 Obesity  
 Diabetes mellitus 
 Congenital hyperlipidemic disorders 
 
In these conditions excess fatty acids spill over into other tissues like 
visceral organs especially liver as called ectopic fat. Ectopic fat get deposited into 
liver to form fatty liver.  
 
Conditions associated with liver damage like 
 Alcoholic liver disease 
 Hepatotoxins (e.g.) Chloroform, Aflatoxin  
 Starvation  
 Chronic diseases (e.g.) tuberculosis  
 Drug induced liver injury (e.g.) methotrexate, steroids, 
halothane. (29)  
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Pathogenesis  
Normally lipids enter into the liver from  
 Diet as chylomicrons (contains triglycerides and phospholipid) 
 Adipose tissues as free fatty acids  
 Minor portion of fatty acids also synthesized from acetyl co-A in the 
liver itself. 
 
 In the liver major part of free fatty acids converted to triglycerides and 
released into circulation as VLDL.  
 
 Any condition which leads to the imbalance between the rate of input and / 
or synthesis of fatty acids in liver and the rate of export/ catabolism will lead to 
the development of fatty liver (or) hepatic steatosis. (33) 
             
           In fatty liver accumulation of triglycerides inside hepatocytes occurs may 
be due to defect in any of the following steps. 
 Increased entry of free fatty acids into liver 
 Increased fatty acid synthesis by liver 
 Decreased ketone body production from free fatty acids leads to 
increased triglyceride formation in liver 
 Defect in VLDL formation  
 Block in lipoprotein (VLDL) secretion from liver 
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Morphological features of fatty liver  
 Macroscopically, the fatty liver is grossly enlarged with rounded margins 
and the cut section shows pale yellow to yellow in colour. 
 
 Microscopically, numerous lipid vacuoles present in cytosol of the 
hepatocytes. These vacuoles are small in size and present around the nucleus at 
initial stages. This is called microvesicular hepatic steatosis.  
 
 But when the condition progresses the lipid vacuoles enlarge and pushes 
the nucleus to periphery, which is called macrovesicular hepatic steatosis. 
Sometimes this large fatty vacuoles may rupture and form fatty cysts.  
 
 The fat inside the hepatocytes can be demonstrated by fat specific stains 
like Sudan dyes and Oil red O. (30) 
 
Investigations 
 Ultra sonogram is the most commonly used investigation to diagnose fatty 
liver. CT, MRI are the alternative investigation available but not routinely used. 
 
Liver biopsy is the gold standard investigation to confirm fatty liver. 
 
Ultra sonographic view of fatty liver appears bright due to increased 
echogenicity. It provides a qualitative assessment of hepatic fat content. Increased 
attenuation of the ultrasound beam causes poor visualization of posterior part of 
the liver, portal and hepatic veins.  
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Grading  
Grade 1 – mild  
o Echogenicity is slightly increased with normal visualization of 
diaphragm and intra hepatic vessels.  
Grade 2 – moderate  
o Echogenicity is moderately increased with slightly 
impairedvisualization of diaphragm and intra hepatic vessels.  
Grade 3 – severe  
o Echogenicity is markedly increased with poor or non visualization of 
diaphragm and intra hepatic vessels and posterior portion of the liver.  
 
 When compared to CT and liver biopsy overall accuracy of liver 
ultrasound is 85-89% and specificity is 56-93 %. (34) 
 
Complications 
Non alcoholic fatty liver disease ( NAFLD) is a wide spectrum of disorders 
with presence of hepatic steatosis. NAFLD is one of the most common causes of 
chronic liver disease and it approximately affects 3-5 % of the population. Fatty 
liver disease is not commonly detected at initial stages because it is completely 
asymptomatic.  
 
 Once the condition progress hepatic steatosis can leads to non alcoholic 
steatohepatitis  (NASH) , decompensated liver disease, cirrhosis of liver. More 
than 90 percent of cirrhosis of unknown origin is probably due to NFALD.  Over 
years later NAFLD may progress to Hepatocellular carcinoma. (35) 
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Complications of Non Alcoholic Fatty Liver Disease (NAFLD)(36) 
 
 
MANAGEMENT OF HYPERLIPIDEMIA  
             Dietary management should be the initial and first line of treatment option 
in hyperlipidemia unless the patient is having evident coronary or peripheral 
vascular disease. But patient with familial disease always needs drug therapy.  
 
            Cholesterol, saturated fat and trans fat in the diet increases serum LDL 
level whereas excessive calories intake , increased total fat intake and alcohol 
increases serum triglyceride level.  
 
           Dietary management includes restricting total calories from fat around 20-
25% and saturated fat less than 7% and total cholesterol less than 200mg per day. 
Complex carbohydrate and dietary fibres intake are recommended. These 
restriction decreases serum total cholesterol level by 10 to 20%. 
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 Omega-3-fatty acids found in fish oil can reduce the serum triglyceride 
levels and it has anti inflammatory and anti arrhythmic property. 
 
           Restriction of total protein intake in diet decreases Homocysteine level 
which initiates pro atherogenic changes in vascular endothelium.  
 
Drug therapy in hyperlipidemia 
 Drug therapy in hyperlipidemia is mainly depends on the associated 
metabolic conditions and risk for Atherosclerosis. Dietary management also 
should be continued to get the maximum benefit from drugs.  
 
 Drug therapy should be avoided in pregnant women and lactating mother 
and it is rarely indicated in children below 16 years unless the child have multiple 
risk factors or compound genetic dyslipidemias. 
 
HMG COA REDUCTASE INHIBITORS: STATINS  
 Statins are the most commonly used and most effective treating option for 
dyslipidemia. They act by competitively inhibiting the enzyme HMG CoA 
reductase which is the early and rate limiting step in cholesterol synthesis.  
 
 Statins were first isolated from Penicillium citrinum in 1976. Mevastatin 
was the first statin studied in humans and Lovastatin which was isolated from 
Aspergillus terreus was the first statin approved for human use. Simvastatin and 
pravastatin are derivatives of lovastatin whereas atorvastatin, fluvastatin, 
rosuvastatin and pitavastatin are synthetic compounds. They contain heptanoic 
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acid side chain which is a structural analogue of intermediate form of HMG Co A. 
Since they are structurally similar to HMG Co A they can reversibly and 
competitively inhibit HMG Co A reductase enzyme. 
 
           Lovastatin and simvastatin are lactone prodrugs metabolized in liver to 
active forms and they are less soluble in water. Others drugs like atorvastatin, 
rosuvastatin and pitavastatin are administered in active form itself. 
 
Mechanism of action  
        Statins acts by competitively inhibiting HMG CoA reductase and thereby 
reducing the conversion of HMG CoA to mevalonate which is a early step in 
cholesterol synthesis. Hepatic cholesterol synthesis mainly is decreased by statins 
which results in increased expression of LDL receptor on the surface of the 
hepatocytes. This leads to increased removal of LDL from the circulating blood. 
Statins also reduces serum VLDL and IDL levels and serum triglyceride levels. 
 
           Statins exert cardio protective effect by lowering plasma Cholesterol level. 
Other than lipid lowering effects, statins have pleiotropic effects which are also 
considered to be cardio protective.(37) 
 
 Statins improves the vascular endothelial function by enhancing the 
production of Nitric oxide from endothelial cells. This action is independent of 
cholesterol lowering effects of statin.  
 
 Statins enhance the plaque stability, prevents plaque rupture and thrombus 
formation thereby prevents the coronary vascular events. Statins inhibits the 
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monocytes infiltration and decrease the secretion of matrix metalloproteinase 
which is the enzyme weakens the Atherosclerotic plaque.  
       
 Statins have anti inflammatory action which is independent of cholesterol 
lowering action. (38) 
 
 Oxidation of lipoproteins inhibited by statins thereby prevents the uptake 
of oxidised lipoproteins uptake by Macrophages and Foam cell formation.  
 
 Statins prevents the formation of thrombi by inhibiting the aggregation of 
platelets. It also decreases the fibrinogen level and decrease the incidence of 
venous thromboembolism.  
 
 Statins inhibits smooth muscle cell proliferation and enhance the apoptosis. 
This may have a role in cancer treatment. 
 
 Statins decrease the accumulation of A beta proteins in neuron. This may 
have a role in Alzheimer’s disease management. (39) 
 
Pharmacokinetics 
 Statins are given orally and after oral administration it has variable 
absorption rate range from 30-85%.  All type of the statins except simvastatin and 
lovastatin administered in beta hydroxyacid form which inhibits HMG CoA 
reductase directly. Simvastatin and lovastatin administered in inactive lactone 
form which is metabolized in liver to active form. Statins have high hepatic 
uptake and variable systemic bioavailability of  5-30%. Statins and their 
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metabolites have high plasma protein binding capacity of more than 95 %. 
Atorvastatin and rosuvastatin has longer t ½ of 20 hours and all other statins have 
only 4 hours which is responsible for high cholesterol lowering property of 
Atorvastatin and rosuvastatin. After metabolism more than 70 % of the 
metabolites excreted by liver through feces. 
 
Adverse effects  
 Hepatotoxicity  
 Statin induced hepatotoxicity varies from asymptomatic elevation of 
hepatic enzymes to liver failure (40), (41). The incidence of asymptomatic elevation 
of hepatic transaminase enzyme among statin taking individuals is 1-3 % and 
FDA has reported 30 liver failure cases in between the year of 1987-2000 in statin 
taking patients.(42) 
 
 Myopathy  
 Myopathy is the most common adverse effect associated with statin use (41). 
42 deaths were reported by FDA in statin used patients by rhabdomyolysis. The 
risk of myopathy and rhabdomyolysis increases when it is used in patients with 
advanced age, renal dysfunction, hepatic dysfunction, peri operative period, 
multisystem disease like diabetes and hypothyroidism(43). the risk also increases 
when the dose of the statin use increased. A drug which affects the metabolism of 
statins like fibrates, digoxin, cyclosporine, warfarin, azole antifungals, macrolide 
antibiotics are also increases the chance of myopathy when it is taken along with 
statins.  
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 Gemfibrozil when used along with statins most commonly associated with 
statin induced myopathy because inhibits the uptake of active form (hydroxyacid 
form) of statins by hepatocytes and increases the statin concentration.  
                
 Atorvastatin, lovastatin and simvastatin are mainly metabolized by 
cytochrome P 3A4 and cytochrome P3A5. Macrolide antibiotics, cyclosporine and 
azole antifungal drugs interferes with statin oxidation by cytochrome P3A4 and 
increases its plasma concentration and thereby increase the chance of myopathy.  
 
o Statins may also cause non-immunological skin reaction.  
o In pregnancy and lactation statin use is not advised. (44) 
 
USES OF STATINS: 
 Atherosclerosis 
Atherosclerosis is an inflammatory disorder of arterial wall. Initially there will 
be depostion of fat in the endothelium.This leads to abnormal endothelial 
function which is followed by inflammatory cell infiltration specifically 
macrophages which engulfs oxidised LDL and forms Form cells or otherwise 
called lipid laden macrophages.  
 
Machrophages mediated inflammation and smooth muscle proliferation in 
arterial wall leads to atherosclerotic plague formation. This can obstruct the 
arterial lumen or otherwise can leads to distal embolisation resulting in 
ischemia of the organ which is supplied by the artery. This is the most 
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common mechanism how atherosclerosis can cause stroke, Myocardial 
infarction and Acute lower limb ischemia.  
 
 Acute limb ischaemia 
 Thrombotic limb ischemia treated with intravenous heparin, anti platelet drugs 
and high dose statins.  
 
 Hypercholesterolemia  
 Hypercholesterolemia is considered to be one of the major risk factor for 
Atherosclerosis and statins are used as primary prevention. It is used in 
patients with elevated serum cholesterol levels but don’t even have the history 
of atherosclerotic disease.  
 
 Statins are also used as secondary prevention in patients with established 
atherosclerotic disease with or without elevated serum cholesterol level.  
 
 Diabetic dyslipidemia 
 Diabetic dyslipidemia is usually presents as increased TG level, low HDL 
level with moderately elevated TC and LDL levels.  
 
 Patients with type 2 diabetes mellitus in the age group of above 40 years 
treated with statins irrespective of the serum cholesterol levels. (45) 
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 Hyperlipidemia 
 Statins are commonly used cholesterol lowering agent in both primary or 
familial and secondary hyperlipedemia. Overall statins reduces serum LDL 
levels up to 60% and TG levels up to 40% and increases HDL up to 10%. 
 
 Hypertension 
 Statins are used as an adjuvant therapy in hypertensive patients who are at the 
higher risk of developing cardio vascular disease.  
 
 Renal artery stenosis 
 The etiology for renal artery stenosis is generally atherosclerosis; so statins are 
used along with anti hypertensive medicine and low dose aspirin.  
 
 Stroke prevention 
 Patients with ischaemic stroke are treated with long term anti platelet drugs 
and statins. 
 
 Peripheral vascular disease  
       Statins used in peripheral vascular disease of lower limb increases the 
walking distance. 
 
 Smokers 
 Statins when used in smokers decreases the coronary events.  
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 Metabolic syndrome 
 Statins are used in metabolic syndrome to reduce coronary heart disease 
mortality.  
 
 Post myocardial infarction 
 Statins are started as soon as coronary heart disease is diagnosed and used for 
long duration. Statins are also used before Angioplasty.(46) 
 
Fibric acid derivatives: Fibrates  
 Gemfibrozil and Fenofibrate are commonly used fibrates. It acts as ligand 
to PPAR alfa which is a nuclear transcription receptor and upregulates lipoprotein 
Lipase and Apo A II. 
 
 This leads to increased fatty acid oxidation in liver and decreased VLDL 
production. So it is much useful in treating hypertriglyceridemia where serum 
VLDL is increased. Fibrates also useful in treating drug induced 
hypertriglyceridemia due to protease inhibitor therapy. 
                 
 Rashes, myopathy, hypokalemia, GI symptoms, elevation of 
aminotransferase enzyme are some adverse effects. Risk of myopathy increased 
when fibrates given along with statins. 
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Niacin 
 Niacin decreases LDL, TGs level and it is the only agent decreases LPa 
level also. It is used commonly in combination with statins and resins in 
conditions like familial hypercholesterolemia. 
 
 Cutaneous vasodilatation, flushing, warmth sensation, rashes, dry skin are 
some common adverse effects.  
 
 Hyperuricemia, red cell macrocytosis, platelet deficiency, arrhythmias are 
some serious adverse effects of niacin. 
 
Bile acid binding resins 
 Colestipol, cholestyramine, colesevelam are some resins used. 
 
 They are useful only to treat isolated increased LDL levels and 
hypertriglyceridemia and VLDL levels may worsen with resins. 
              
 They acts by binding to bile acids in the intestine and prevents its re 
absorption which promotes increased excretion. This leads to increased 
conversion of bile acids from cholesterol by hydroxylation.  
 
             Resins also increases the Glucagon like peptide-1 from intestine and 
promotes insulin secretion.  Also useful in treating pruritis due to bile salt 
accumulation and in digitalis toxicity.  
 
            Constipation, abdominal bloating, heart burn, hypoprothrombinemia are 
some adverse effects. 
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            Resins will prevent the absorption of many drugs so any drug has to be 
given one hour before or two hour after the intake of resins. 
 
Intestinal sterol absorption inhibitor 
 Ezetimibe inhibits the intestinal absorption of cholesterol and phytosterol 
by acting transporter called NPC1L1. It undergoes enterohepatic circulation and 
plasma concentration increased when taken along with fibrates. 
 
            Ezetimibe have synergistic activity along with statins and produces up to 
25% reduction in serum LDL level. 
 
  
Objectives 
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OBJECTIVES 
 
PRIMARY OBJECTIVE: 
 To assess the prevalence of fatty liver changes in patients taking tablet 
Atorvastatin  
 
SECONDARY OBJECTIVE: 
 To look for the symptoms of various adverse effects of tablet 
Atorvastatin. 
 
  
Methodology 
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METHODOLOGY 
 
STUDY DESIGN 
           This study is an Observational, Cross sectional study in patients taking tab. 
Atorvastatin. 
 
STUDY CENTRE  
            Institute of pharmacology in collaboration with Institute of cardiology, 
institute of internal medicine and Institute of Diabetology, Rajiv Gandhi 
Government General Hospital, Madras medical college, Chennai. 
 
STUDY DURATION 
 The study was carried out from July 2017 to January 2018 
 
SAMPLE SIZE 
 Totally 201 patients  
 
STUDY SUBJECTS 
 Adult Patients attending Cardiology OPD, Diabetology OPD, Medicine 
OPD in RGGGH, CHENNAI. 
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ELIGIBILITY CRITERIA 
INCLUSION CRITERIA 
 Age group of 18-80 years 
 Sex- both male and female 
 Patients who are taking Tablet. Atorvastatin more than two years. 
 Patients who is willing to participate in this study. 
 
EXCLUSION CRITERIA 
 Patients who are with chronic liver disease 
 Patients with chronic alcoholism 
 Patients taking other hepatotoxic drugs 
 Patients who are not willing to participate and give consent 
 
STUDY PROCEDURE 
              This study will be conducted after obtaining the approval from the 
Institutional Ethics committee, Madras Medical College. 
 
             Patients will be explained about the study purpose and the procedures. 
Informed consent will be obtained from the patients who are willing to participate 
in the study in the prescribed format in the regional language. 
           
 The demographic details of the patients will be obtained. Patients who 
fulfil the inclusion and exclusion criteria will be enrolled for study. 
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INVESTIGATIONS 
 Ultrasound abdomen (Liver) 
 Lipid profile 
 Liver function test 
 Questionnaire regarding symptoms of adverse effect of Atorvastatin.    
 
  
Results 
  
59 
 
 
 
RESULTS 
 
 
 
 This study was conducted to assess the prevalence of fatty liver changes 
and to look for the symptoms of other various adverse effects of tab. Atorvastatin  
 
 236 patients were screened  
 35 patients were excluded based on Exclusion criteria 
 201 patients were enrolled and assessed for fatty liver changes and other 
adverse effects 
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           TABLE 1 
 
Total no. of Patients Diabetic Non diabetic 
201 115 86 
 
 Table 1 shows total number of diabetic and non diabetic patients. 
 
 
 
FIGURE 1 
 
 
 
 
 
 Figure 1 is the graphical representation of table 1. 
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TABLE 2 : AGE DISTRIBUTION 
 
Age in  years No. of patients percentage 
18-40 3 1.49 % 
40- 50 39 19.40 % 
50-60 74 36.82 % 
60-70 69 34.32 % 
70-80 16 7.96 % 
 
 Table 1 shows the age distribution of the patients 
 Age group 50-60 had more number of patients followed by 60-70 years. 
 
FIGURE 2: AGE DISTRIBUTION 
 
           
 
 
 
 Figure 2 is the graphical representation of table 2. 
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TABLE 3  :  SEX DISTRIBUTION 
 
Sex distribution No. of patients Percentage 
Male 92 45.77 % 
Female 109 54.22 % 
Total No. of Patients 201 100 % 
 
 Table 3 shows the sex distribution of the patient 
 Females were more in number compared to males 
 
                             
 
FIGURE 3  :  SEX DISTRIBUTION 
 
 
 
 
 
            
 Figure 3 shows the graphical representation of table 3. 
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TABLE 4 
 
 Fatty liver positive Fatty liver negative 
Diabetic patients 35.65% 64.35% 
Non-diabetic patients 30.23% 69.77% 
 
 Table 4 shows the percentage of patients having fatty liver in Diabetic and 
non diabetic patients 
 Number of diabetic patients shows more percentage of fatty liver changes 
 p value equals 0.51 
 
 
FIGURE 4 
 
 
 
 
 Figure 4 shows the graphical representation of table 4. 
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TABLE 5 
 
Duration No of patients Percentage 
Fatty liver 
positive Percentage 
2-3 Years 81 40.30% 21 25.93% 
3-4 Years 73 36.32% 27 36.99% 
4-5 Years 32 15.92% 13 40.63% 
More than 5 years 15 7.46% 6 40.00% 
 
 Table 5 shows the duration of patients taking tab. Atorvastatin in years 
 Most number of patients in the duration of 2-3 years 
 Fatty liver positive percentage is more in 4-5 year duration and more than 5 
year duration patients 
 
FIGURE  5 
 
 
 
 Figure 5 is the graphical representation of table 5 
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TABLE 6: LIPID PROFILE OF NON DIABETIC PATIENTS 
 
Lipid 
Non diabetic 
Normal range Study group range Mean 
Total Cholesterol <200 112-286 186.1±36.8 
Triglyceride 40-160 90-297 167.7±55.0 
HDL 40-60 18-58 34.8±9.8 
LDL <100 57-176 95.4±31.7 
 
 Table 6 shows the mean value of the lipid profile in non diabetic patients 
 All values in mg/dl 
 Totally 86 non diabetic patients were examined 
 
TABLE 7  :  LIPID PROFILE OF DIABETIC PATIENTS 
 
Lipid profile 
Diabetic 
Normal range Study group range Mean 
Total Cholesterol <200 127-384 209.3±54.9 
Triglyceride 40-160 89-412 196.0±54.8 
HDL 40-60 19-58 32.6±9.8 
LDL <100 66-214 111.3±36.1 
 
 Table 7 shows the lipid profile values in diabetic patients 
 All values in mg/dl 
 Totally 115 diabetic patients were examined 
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TABLE 8 : COMPARING THE LIPID PROFILE VALUE BETWEEN 
DIABETIC AND NON DIABETIC PATIENTS 
LIPID PROFILE 
VALUES 
DIABETIC 
PATIENTS 
NON DIABETIC 
PATIENTS P VALUE 
Total Cholesterol 209.3±54.9 186.1±36.8 0.0008 
Triglyceride 196.0±54.8 167.7±55.0 0.0004 
HDL 32.6±9.8 34.8±9.8 0.1900 
LDL 111.3±36.1 95.4±31.7 0.0013 
 
 Table 8 shows the comparison of lipid profile values between diabetic and 
non diabetic patients. 
 There is significant difference in total cholesterol, triglycerides and LDL 
values between diabetic and non diabetic patients. 
 
FIGURE 6: COMPARING THE LIPID PROFILE VALUE BETWEEN 
DIABETIC AND NON DIABETIC PATIENTS 
 
 
 Figure 6 shows the comparison of mean lipid profile values between non 
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TABLE 9 : LIVER FUNCTION TEST IN  FATTY LIVER  POSITIVE 
PATIENTS 
LIVER 
FUNCTION 
TEST 
FATTY LIVER POSITIVE PATIENTS 
Normal range Study group range Mean 
SGOT 12-38 12-202 55.51±53.33 
SGPT 7-41 10-241 54.08±52.99 
ALP 35-130 39-148 74.62±28.85 
 
 Table  9 shows the LFT values in Fatty liver positive patients 
 All values in IU/L 
 Totally 67 Fatty liver positive patients were examined. 
 
 
TABLE  10: LIVER FUNCTION TEST IN FATTY LIVER  NEGATIVE 
PATIENTS 
LIVER 
FUNCTION 
TEST 
FATTY LIVER NEGATIVE PATIENTS 
Normal range Study group range Mean 
SGOT 12-38 11-112 31.83±20.31 
SGPT 7-41 11-146 34.13±19.93 
ALP 35-130 35-136 71.12±22.09 
 
 Table 10 shows the LFT values in Fatty liver negative patients 
 All values in IU/L 
 Totally 134 Fatty liver negative patients were examined. 
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TABLE 11 : COMPARISON OF LFT VALUES BETWEEN FATTY LIVER 
POSITIVE AND NEGATIVE PATIENTS 
 
LIVER 
FUNCTION 
TEST 
FATTY LIVER 
POSITIVE 
FATTY LIVER 
NEGATIVE P VALUE 
SGOT 55.51±53.33 31.83±20.31 0.0002 
SGPT 54.08±52.99 34.13±19.93 0.0002 
ALP 74.62±28.85 71.12±22.09 0.34 
 
 Table 11 shows the comparison of SGOT, SGPT and ALP levels between fatty 
liver positive and fatty liver negative patients. 
 There is significant difference in SGOT, SGPT levels between fatty liver 
positive and fatty liver negative patients.  
 
FIGURE 7 : COMPARISON OF LFT VALUES BETWEEN FATTY LIVER 
POSITIVE AND NEGATIVE PATIENTS 
 
 
 Figure 7 is the graphical representation of table 11. 
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TABLE 12: QUESTIONARRIE FOR THE ADVERSE DRUG REACTION 
OF T.ATORVASTATIN 
 
SYMPTOMS NO OF PATIENTS 
Fatigue 71 
Myalgia 58 
Joint pain 41 
Dysphagia 41 
Nausea 3 
Insomnia 35 
Memory disturbances 12 
Headache 20 
Numbness 14 
Skin dryness 7 
 
 Table 12 shows the adverse drug reactions of T.Atorvastatin 
 Fatigue is the most common adverse reaction followed by myalgia 
 
FIGURE 8 
 
 
 Figure 8 is the graphical representation of table 12. 
 
 
0
10
20
30
40
50
60
70
80
ADVERSE EVENTS
N
O
 O
F PA
TIEN
TS
70 
 
 
TABLE 13: CAUSALTY ASSESSEMET OF ADVERSE DRUG 
REACTIONS- WHO UMC SCALE 
 
ADR Certain Probable Possible Un-likely 
Un-
classified 
Un-
classifiable 
Fatigue  18 53    
Myalgia  21 37    
Joint pain  13 28    
Dysphagia  7 34    
Nausea   3    
Insomnia  17 18    
Memory 
disturbances  11 1    
Headache   20    
Numbness  14     
Skin 
dryness   6 1   
 
 Table 13 shows the various adverse effects of tab. Atorvastatin and its 
causalty assessment by WHO scale. 
 Fatigue being the most common adverse effect and most of the adverse 
effects comes under possible category. 
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TABLE 14: SEVERITY ASSESSENENT OF ADVERSE DRUG 
REACTIONS BY MODIFIED HARTWIG SIEGEL SCALE 
 
ADR MILD MODERATE SEVERE 
Fatigue 71   
Myalgia 47 11  
Joint pain 36 5  
Dysphagia 37 4  
Nausea 2 1  
Insomnia 31 4  
Memory 
disturbances 12   
Headache 14 6  
Numbness 14   
Skin dryness 7   
 
 Table 14 shows the severity assessment of various adverse effects of 
tab.Atorvastatin by Modified Hartwig Siegel Scale. 
 Most of the adverse drug reactions come under mild category. 
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DISCUSSION 
 
 Statins are one of the most commonly used drug for longer duration for 
various conditions like Dyslipidemia, Cardio vascular diseases, stroke, peripheral 
vascular diseases, Atherosclerosis, Hypertension. (47) 
 
 Statins also proposed to have a role in Parkinsons disease, Alzhiemers 
disease, Multiple sclerosis, Inflammatory bowel disease, breast cancer, 
rheumatoid arthritis, COPD. 
 
 Since statins have wide scale of use and being used for longer duration and 
so it may cause many adverse effects and some of the adverse effects are not 
documented in the literatures.  
 
 Fatty liver changes are commonly found in patients taking statins due to 
long term use and these adverse effects are not documented in the literatures. It 
may cause serious complications like cirrhosis; de compensated liver disease and 
even liver failure in later stages.  
 
 In this study the prevalence of fatty live changes and alteration in lipid 
profile was analysed. A total of 201 patients taking tab. Atorvastatin for more than 
two years were included in the study in the age between 18-80 years. 
 
 The age distribution showed more number of patients above 50 years and 
in sex distribution female patients are slightly higher in number than male 
patients. 
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 Ultra sonogram of liver was done for the total 201 patients and 67 patients 
(33.33%) had found to have fatty liver changes.  The results showed the 
percentage of fatty liver positive patients are more among those who take statins 
for more than 4 years and it increases with the duration of treatment increases. 
 
 Out of 201 patients 115 were diabetic and 86 were non diabetic. Among 
diabetic patients 35.65% had fatty liver and in non diabetic patients 30.23% had 
fatty liver. The difference among diabetic and non diabetic patients is statistically 
not significant (P value 0.51) which shows that fatty liver changes are due to 
statins and not due to Diabetes mellitus. 
 
 The mean Lipid profile values (Total cholesterol, LDL, HDL, 
Triglycerides) of the 201 patients showed overall increase from normal range. 
When comparing the mean values of diabetic and non diabetic patients there is 
statistically significant increase in serum total cholesterol, LDL and TG levels 
among diabetic patients.   
 
 Acetyl coA derived from glucose metabolism forms the building block for 
cholesterol synthesis and fatty acid synthesis. Inhibition of cholesterol synthesis 
by statins increases the synthesis of fatty acids in liver. Excess production of fatty 
acids increases the production of triglycerides which enters the systemic 
circulation. The excess TGs get deposited as ectopic fat in various organs 
especially in liver and forms Fatty liver. 
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                                                          ACETYL COA 
                                                                                         STATINS                                                                                        
AcetylcoA carboxylase                                                  HMG COA reductase 
 
 
                  FATTY ACID                                                    CHOLESTEROL 
             
 Estimation of liver enzymes (SGOT, SGPT, and ALP) among the fatty 
liver positive and fatty liver negative individuals showed the significant elevation 
of SGOT and SGPT levels among fatty liver positive patients. These differences 
are statistically significant with the P value of 0.0002 which implies that fatty 
liver changes are associated with liver injury and elevated liver enzymes. 
 
               In this study 33.33% of patients showed positive for fatty liver changes 
and overall increase in TG level were found in the patients.  
 
 This proves the hypothesis that statins indirectly stimulating fatty acid 
synthesis in liver by inhibiting the synthesis of cholesterol. Long term effect of 
fatty liver and increased TG level can cause serious complications like cirrhosis, 
central obesity and vascular diseases. 
 
 From this study we understand that the fatty liver changes are commonly 
found in patients taking statins for chronic duration and so Fatty liver can be 
included in the adverse effect profile of statins. 
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 Most of the drug induced liver injury and fatty liver will become normal 
once the offending drug is withdrawn.(48) So restricted use of statins and 
avoidance of longer duration of use in various indications can minimise the drug 
induced fatty liver among the patients and also prevents the long term 
complications of statins and fatty liver.      
 
 Statins by inhibiting cholesterol and coenzyme Q synthesis can produce 
many adverse effects like chronic muscle pain, fatigue, joint pain, numbness, 
memory problems, mood disorders, sleep disturbance, impaired immune function 
and impotence, chronic fatigue syndrome, hypertension, cardiomyopathy an some 
of the adverse effects are not mentioned in the literatures. 
 
 In this study a questionnaire is given to all the participants regarding the 
symptoms of adverse effect profile of tab. Atorvastatin. Out of 201 patients, 
almost all the patients had at least one adverse effect symptoms. Most number of 
patients had fatigue (71) as an adverse effect. Second most common symptom is 
Myalgia (58). Joint pain, Dysphagia and sleep disturbances were also more 
commonly present among many patients.  
 
           The adverse effects were analysed with WHO causalty assessment scale 
and most of the ADR comes under possible category and some comes under 
probable category. In modified hartwig siegel scale most of the adverse effects 
comes in mild category.  
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              The above mentioned adverse effects fatigue, myalgia, joint pain, 
Dysphagia and sleep disturbances will affect the patients quality of life(49). They 
are present most commonly among the patients taking statins for longer duration 
so cautious use of statins and avoidance of chronic use will minimise the overall 
incidence of these adverse effects and will improve the patients quality of life. 
    
  
Conclusion 
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CONCLUSION 
 
 Inhibition of cholesterol synthesis by statins increases the synthesis of 
Fatty acids. The excess fatty acids get deposited in visceral organs especially liver 
as ectopic fat causes fatty liver. 
 
 This occurs over long term use of statins; therefore the use of statins should 
be restricted with proper indications and for a short term.  
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Appendices 
APPENDIX-1 
 
LIST OF ABBREVIATIONS 
 
HMG-COA          - 3- Hydroxy -3- methyl glutaryl coenzyme A 
ATP - Adenosine tri phosphate 
ACC - Acetyl coa carboxylase 
NASH - Non alcoholic steato hepatitis 
DCLD - Decompensated liver disease 
MUFA - Mono unsaturated fatty acids 
PUFA - Poly unsaturated fatty acid 
VLDL - Very low density lipoprotein 
LDL - Low density lipoprotein 
HDL - High density lipoprotein 
IDL - Intermediate density lipoprotein 
DHA - Docosa hexaenoic acid 
TAG - Tri acyl glycerol 
NADPH - Nicotinamide adenine dinucleotide phosphate 
DHAP - Dihydroxy acetone phosphate  
HSL - Hormone sensitive lipase 
FFA - Free fatty acid 
SREBP - Sterol regulatory element binding protein 
MTP - Microsomal triacyl glycerol transfer protein 
ACAT - Acetyl coA : cholesterol acyl transferase 
DILI - Drug induced liver disease 
NAFLD - Non alcoholic fatty liver disease 
HCC - Hepato cellular carcinoma 
  
APPENDIX-2 
CASE REPORT FORM 
 
PREVALENCE OF FATTY LIVER CHANGES AND OTHER VARIOUS 
ADVERSE EFFECTS IN PATIENTS TAKING TABLET ATORVASTATIN –A 
CROSS SECTIONAL OBSERVATIONAL STUDY  
 
PATIENT DEMOGRAPHY: 
NAME:    AGE/SEX:   OP NO: 
OCCUPATION:   ADDRESS:   CONTACT NO: 
 
DIAGNOSIS: 
S. 
NO 
INCLUSION  
CRITERIA YES NO 
EXCLUSION  
CRITERIA YES NO 
1. Age group of 18-80 years   
Patients who are with 
chronic liver disease   
2. 
Patients who are taking 
Tablet. Atorvastatin 
more than two years. 
  Patients with chronic alcoholism   
3. 
Patients who is willing 
to participate in this 
study. 
  Patients taking other hepatotoxic drugs   
4.    
Patients who are not 
willing to participate and 
give consent 
  
 
 
 
SUBJECT:             INCLUDED                   EXCLUDED    
 
 
 
REASON IF EXCLUDED:  
 
SIGNATURE OF PRINCIPAL INVESTICATOR:  
 
MEDICAL HISTORY: 
 
 
VITAL SIGNS: 
 
PULSE RATE: 
BLOOD PRESSURE: 
 
GENERAL EXAMINATION: 
SYSTEMIC EXAMINATION: 
 
INVESTICATIONS 
 
 Liver function test: 
 
 Lipid profile: 
 
ULTRASOUND LIVER: 
 
 
ADVERSE DRUG REACTION MONITERING   OF TABLET ATORVASTATIN: 
 
DRUG    USED        :      ATORVASTATIN 
 
DOSE:                            FREQUENCY:                DURATION: 
 
INDICATION:              
  
 
Do you have any of the following symptoms? 
 
S.NO SYMPTOMS YES NO DON’T KNOW 
1.  Nausea    
2.  Dysphagia    
3.  Headache    
4.  Myalgia    
5.  Joint pain    
6.  Fatigue    
7.  Insomnia    
8.  Memory disturbances    
9.  Numbness    
10.  Skin dryness    
11.  Others    
 
Are you taking any other medications?  
 
1) YES          2) NO 
 
If yes ------------------------------------- 
 
 
 
WHO CAUSALITY ASSESSMENT SCALE   
 
 
 
NARANJO ASSESSMENT SCALE  
APPENDIX-3 
INFORMED CONSENT FORM 
 
PREVALENCE OF FATTY LIVER CHANGES AND OTHER VARIOUS ADVERSE 
EFFECTS IN PATIENTS TAKING TABLET ATORVASTATIN –A CROSS 
SECTIONAL OBSERVATIONAL STUDY  
 
Name of the Participant: 
I, _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am over 
18 years of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in this study. 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital.  
6. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC.I understand that they are publicly 
presented. 
7. I have understand that my identity will be kept confidential if my data are 
publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
 
1. Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
 
Name ___________________Signature/Guardian_________________ Date_______ 
 
2. Name and Signature of impartial witness (required for illiterate patients): 
 
Name ______________________ Signature_________________ Date_______ 
 
Address and contact number of the impartial witness: 
 
3. Name and Signature of the investigator or his representative obtaining consent: 
 
Name _____________________ Signature_________________ Date __________ 
APPENDIX-4 
 
INFORMATION TO PARTICIPANTS 
 
Title: PREVALENCE OF FATTY LIVER CHANGES AND OTHER VARIOUS 
ADVERSE EFFECTS IN PATIENTS TAKING TABLET ATORVASTATIN –A 
CROSS SECTIONAL OBSERVATIONAL STUDY 
 
Principal Investigator:  
 
Name of Participant: 
 
This study is conducted in Rajiv Gandhi Govt. General Hospital, Chennai. You 
are invited to take part in this study. The information in this document is meant to help 
you to decide whether or not to take part. Please feel free to ask if you have any queries 
or concerns. 
 
The purpose of this study 
Atorvastatin is the most commonly used drug to treat patients with dyslipidemia. 
It is used in many chronic diseases. It inhibits the production of cholesterol and CO 
ENZYME Q both are important physiological component of body. Fatty liver changes 
are commonly found in patients taking statins. This study will help to look for the 
association between the fatty liver and the use of statins also to see the prevalence of 
other adverse effects. 
 
We have obtained permission from the Institutional Ethics Committee.  
 
The study design 
This is an observational study. Clinical examination, initial blood investigation, 
ultrasound abdomen and a questionnaire will be given to the patient. 
 
Study Procedures 
The study involves blood investigations like complete blood count, liver function 
test, blood sugar level, renal function test, and lipid profile and ultrasound abdomen to 
look for liver changes. The above tests are done at one time and there is no follow up or 
visits are needed. The participants are given a questionnaire with basic information 
which can be filled by them. This questionnaire has adverse effects of tablet 
Atorvastatin.  
 
Possible benefits to you  
    This study may help to identify any adverse effect or abnormal parameters you have in 
blood investigation and ultrasound abdomen.. 
 
Possible benefits to other people 
The results of the research may help to restrict the use of statins in liver disease 
patient and increase the knowledge about adverse affects of statins. 
 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and your 
medical history). By signing this document, you will be allowing the research team 
investigators, other study personnel, sponsors, Institutional Ethics Committee and any 
person or agency required by law like the Drug Controller General of India to view your 
data, if required. 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
Decision to not participate in the study  
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken care of 
and you will not lose any benefits to which you are entitled. 
 
Decision to withdraw from the study once started  
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving any 
reasons. However, it is advisable that you talk to the research team prior to stopping the 
treatment/discontinuing of procedures etc.The expenditure for the treatment and 
investigation for this study will not be collected from you. The results of this study will 
be informed to you at the end of the study. 
 
 
Signature of Investigator                                                     Signature of Participant  
 
Date                                                                                         Date 
 
  
 
 
  
  
APPENDIX-5 
ETHICAL COMMITTEE APPROVAL 
 
